Biosimilar GP2013 Is Equivalent to Rituxan as Lymphoma Therapy, Phase 3 Trial Shows

News

Lymphoma patients’ response to Sandoz’s biosimilar therapy GP2013 was similar to their response to the treatment from which it is derived, Genentech’s Rituxan (rituximab), a Phase 3 clinical trial indicates. Sandoz presented ... Read more

September 13, 2017

Study Identifies Factors Associated with Young Cancer Survivors’ Reduced Ability to Work

News

Depression, fatigue, and reduced physical quality of life are among the factors that limit young cancer survivors’ ability to work, according to a Norwegian study. Side effects of treatment can ... Read more